NNC0519-0130
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.
Novo Nordisk · Phase 1 · Completed · Enrollment 161
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Single ascending dose (SAD) part | T2D only | n/r | 18 | n/r | n/r |
| Multiple ascending dose (MAD) QD part | T2D only | n/r | 18 | n/r | n/r |
| Type 2 diabetes (T2D) part | T2D only | n/r | 18 | n/r | n/r |
| MAD QW part | T2D only | n/r | 18 | n/r | n/r |